Juvenescence Therapeutics Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Juvenescence Therapeutics Limited - overview
Established
2016
Location
Dublin, -, Ireland
Primary Industry
Biotechnology
About
Based in Dublin, Ireland, Juvenescence Therapeutics Limited focuses on developing innovative therapeutics aimed at enhancing healthspan and lifespan through advanced medical solutions. Founded in 2016, Juvenescence Therapeutics Limited specializes in the development of therapeutics aimed at extending health and life. The company is headquartered in Dublin, Ireland. Its CEO, Richard Marshall, has a background in founding other companies prior to establishing Juvenescence.
The firm has completed 6 deals, with the most recent funding round being a Series B round in May 2025, raising USD 150. 000 mn. This round was led by M42 Ltd. , with participation from several additional investors including Foresite Capital, Grok Ventures, IPGL, and Salica Investments.
Juvenescence Therapeutics Limited offers a range of innovative therapeutics designed to tackle specific health challenges. Their flagship product provides advanced solutions tailored for efficiency and effectiveness, catering to a diverse clientele from small to medium-sized enterprises (SMEs) to large corporations. The company's products are strategically positioned in markets across North America, Europe, and Asia-Pacific, focusing on user experience and practical application to enhance productivity. The company operates a revenue model based on direct-to-consumer sales and B2B partnerships.
Clients access their solutions via a subscription-based service, providing continuous updates and support. Certain products are also available through licensing agreements, enabling businesses to integrate the technology into their operations. Pricing plans are structured to accommodate the needs of both small businesses and larger enterprises, facilitating a steady revenue stream while fostering long-term customer relationships. Juvenescence Therapeutics Limited plans to utilize the USD 150.
000 mn raised in its Series B funding on May 10, 2025, to advance its portfolio of therapeutics into clinical development and enhance its core medicine pipeline. The company is also focused on expanding into new geographic markets, with efforts aimed at further penetrating North America and Europe by late 2026. Upcoming product launches are being designed to meet the evolving needs of the market, ensuring a robust pipeline going forward.
Current Investors
M42 Ltd., Foresite Capital, Apeiron Investment Group
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.juvlabs.com/
Total Amount Raised
Subscriber access only
Juvenescence Therapeutics Limited - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Juvenescence Therapeutics Limited | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.